• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 509690 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414169124 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414169124 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Top 3 Companies in the Biotechnology Industry With the Highest Future Earnings Growth (GHDX, ACOR, LGND)

Published on Thu, 05/30/2013 - 10:31
By Peter Chu

Below are the three companies in the Biotechnology industry with the highest future earnings growth. The growth of earnings per share (next fiscal year estimated vs. current fiscal year estimated) is important to gauge future profitability and relative value. Higher EPS growth generally justifies higher earnings multiples.

Genomic Health (NASDAQ:GHDX) is highest with future earnings growth of 126.8%. Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer. The Company's diagnostic services provide information on the likelihood of disease recurrence and response to certain types of therapy.

Genomic Health (NASDAQ:GHDX) defies analysts with a current price ($37.54) 4.4% above its average consensus price target of $35.88. The stock should find initial support at its 50-day moving average (MA) of $31.25 and further support at its 200-day MA of $30.86.

Acorda Therapeutics (NASDAQ:ACOR) is next with future earnings growth of 119.9%.

Finishing up the top three is Ligand Pharmaceuticals (NASDAQ:LGND), with future earnings growth of 94.9%.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Stock Investors Sell Off Shares of Tenne...

One of today's stocks on the move is Tenneco (NYSE:TEN), down 1.3% to $53.00. The S&P ...

Stock Investors Sell Off Shares of Conso...

Consolidated Water (NASDAQ:CWCO) is one of today's biggest movers, down 1.3% to $11.82. ...

Shares of MasTec Under Pressure, Down 1....

One of today's notable stocks in decline is MasTec (NYSE:MTZ), down 1.3% to $26.44. Th ...

Taser International Shares Climbing High...

Taser International (NASDAQ:TASR) is one of today's biggest movers, up 1.3% to $15.46. ...

Shares of Bridgepoint Education Under Pr...

Bridgepoint Education (NYSE:BPI) is one of today's biggest movers, down 1.3% to $11.75. ...

Stock Investors Sell Off Shares of BT Gr...

BT Group (NYSE:BT) is one of today's biggest movers, down 1.3% to $59.44. The S&P is t ...

Stock Investors Sell Off Shares of NVR I...

NVR Inc (NYSE:NVR) is one of today's biggest movers, down 1.4% to $1195.00. The S&P is ...

Shares of Banco Santander Receive a Boos...

Banco Santander (NYSE:SAN), a company whose shares are moving quickly, is trading 1.4% ...